Skip to main content
Premium Trial:

Request an Annual Quote

Marina Closes Cequent Facility, Consolidates R&D in Washington

Premium

Marina Biotech announced last week that it has closed its Cambridge, Mass., operations and is consolidating all of its research and development activities at its Bothell, Wash. headquarters.

The company acquired the Massachusetts facility through its 2010 acquisition of Cequent Pharmaceuticals (GSN 4/1/2010).

Marina said that the move would not affect development of Cequent's transkingdom RNAi technology, which will continue in Washington, and that its phase I program for CEQ508, a tkRNA-based treatment for familial adenomatous polyposis, will be unchanged.

Marina President and CEO Michael French said in an e-mail that the company transitioned three positions from the Cambridge facility to Bothell, but added that certain positions associated with maintaining the bacterial component of the tkRNA technology were not relocated since Marina already has that core capability in Washington.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.